Novo Nordisk uses recombinant DNA technology to make innovative products for people. In 1923, we first marketed insulin for commercial use; today, we offer a comprehensive line of human insulin and insulin analog products. We created the world's first insulin pen device, and are now a world leader in production and distribution of these revolutionary insulin delivery systems. Defeating diabetes through innovation. That's our goal.

Novo Nordisk is committed to the concept that people with diabetes are individuals with different needs and preferences so we offer a choice of fully integrated systems.
Our current range of diabetes device includes:

Prefilled Insulin Delivery Systems: